tirzepatide court UPDATE [March 7, 2025]: OFA takes case to appeals as legal battle evolves FDA's tirzepatide decision creates uncertainty court ruling on tirzepatide case – Compounders can no longer produce

She says the VA pharmacy will review this request within 96 hours, and if its denied, the prescriber can make an appeal to the VA care team

In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023

Originally developed as a long-acting analog, tirzepatide exhibits superior receptor activation compared to single incretin agonists, making it a cornerstone molecule in studies exploring glucose homeostasis, energy balance, appetite regulation, and body composition dynamics

doi:10.1002/lary.21851